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Transcriptional networks are critical for the establishment of tissue-specific cellular states
in health and disease, including cancer. Yet, the transcriptional circuits that control carci-
nogenesis remain poorly understood. Here we report that Kruppel like factor 6 (KLF6), a
transcription factor of the zinc finger family, regulates lipid homeostasis in clear cell renal
cell carcinoma (ccRCC). We show that KLF6 supports the expression of lipid metabolism
genes and promotes the expression of PDGFB, which activates mTOR signalling and the
downstream lipid metabolism regulators SREBF1 and SREBF2. KLF6 expression is driven
by a robust super enhancer that integrates signals from multiple pathways, including the
ccRCC-initiating VHL-HIF2A pathway. These results suggest an underlying mechanism for
high mTOR activity in ccRCC cells. More generally, the link between super enhancer-driven
transcriptional networks and essential metabolic pathways may provide clues to the
mechanisms that maintain the stability of cell identity-defining transcriptional programmes
in cancer.
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Renal cancer is responsible for >400,000 new diagnoses and140,000 deaths annually worldwide1. The most commonform of renal cancer, clear cell renal cell carcinoma
(ccRCC), accounts for ~75% of all renal cancers2. Biallelic inac-
tivation of the von Hippel-Lindau (VHL) tumour suppressor gene
is a hallmark event in ccRCC pathogenesis, contributing to ~90%
of sporadic cases3 as well as to hereditary ccRCC in von-Hippel-
Lindau syndrome patients4. The VHL protein mediates protea-
somal degradation of the hypoxia-inducible factor (HIF) alpha
subunits under normoxic conditions, and genetic VHL inactiva-
tion in ccRCC leads to constitutive HIF alpha accumulation and
consequent upregulation of hypoxia-associated genes4. Of the
two major HIF alpha subunits, HIF2A is responsible for driving
ccRCC growth while HIF1A may suppress ccRCC progression4,5.
Histologically, ccRCCs are hyper-vascular due to upregulation of
pro-angiogenic factors such as VEGFA, a downstream target
of the hypoxia pathway. Hence, the development of ccRCC
therapies has focused on inhibiting angiogenesis, and several anti-
angiogenic drugs targeting receptor tyrosine kinases (RTKs)
such as VEGFR and PDGFR have been clinically approved for
ccRCC6. Additionally, small molecule inhibitors targeting HIF2A
have been developed with promising results in some ccRCC
patients7–9.
The mTOR pathway, frequently hyper-activated in ccRCC10,11,
is another clinically relevant target in renal cancer. Two approved
mTOR inhibitors, everolimus and temsirolimus, are licensed for
clinical use in ccRCC patients12,13. However, the mechanisms
underlying increased mTOR activity in ccRCC remain incom-
pletely understood. Genetic analysis of ccRCC has identified
mutations in components of the PI3K-AKT-mTOR signalling
cascade14. For example, PIK3CA and PTEN are mutated in 2–5%
of ccRCCs and some mutations have also been observed in TSC1,
a negative regulator of mTOR15. Furthermore, mutations in
MTOR are found in approximately 6% of ccRCCs14,16. Genetic
alterations are thus likely to contribute to mTOR activation in
ccRCC, although upstream activating signals still seem to be
required in most cases16. The recent generation of double
knockout Vhl−/−;Pbrm1−/− and Vhl−/−;Bap1−/− mouse models
have also identified mTORC1 hyper-activation as a potential
driver of ccRCC17,18. Concomitant loss of VHL and either
PBRM1 or BAP1, two frequently mutated ccRCC genes3,14 could
thus directly lead to increased mTORC1 activity during ccRCC
development. Mutational analyses alone have not, however, been
sufficient to identify patients sensitive to mTOR inhibition19,
suggesting that additional molecular players are involved.
Recent multi-region sequencing efforts have described wide-
spread intratumoral genetic heterogeneity in ccRCC3. Apart from
large chromosome 3p deletions and inactivation of the second
allele of VHL, usually by point mutation, most predicted ccRCC
driver mutations are subclonal3. This suggests that the opportu-
nities for mutation-based therapeutic approaches in ccRCC are
limited to dependencies resulting from inactivation of the VHL
pathway. Given that a significant fraction of ccRCCs display
intrinsic resistance to HIF2A inhibition and anti-angiogenic
agents9,20, a better understanding of the molecular dependencies
of VHL mutant ccRCC is needed. To this end, tissue-specific
transcriptional circuits or lineage dependencies could offer a
viable avenue forward21.
The expression of transcriptional regulators that govern key
biological processes such as cell identity and cell fate is often
associated with large enhancer clusters such as super enhancers22,23.
Super enhancers also regulate cancer phenotypes24,25. In this
study, combining chromatin activation and transcriptomic data
from multiple ccRCC model systems and clinical samples, we find
that one of the strongest super enhancers in ccRCC cells, partially
activated by the ccRCC-initiating VHL-HIF2A pathway, is
associated with the KLF6 locus, a gene encoding a zinc finger DNA-
binding transcription factor of the Kruppel-like family. KLF6
inhibition impairs ccRCC fitness and leads to a profound inhibition
of lipid biosynthetic pathways. KLF6 regulates the expression of
several lipid homeostasis genes. Moreover, by supporting the
expression of PDGFB, an agonist of the mTOR pathway, KLF6
further promotes lipid metabolism by enhancing the activation
of the key lipid metabolic regulators SREBF1 and SREBF2. KLF6
and mTORC1 thus co-regulate lipid homeostasis, consequently
supporting ccRCC growth. The PDGF and mTOR pathways are
clinically relevant therapeutic targets in ccRCC. Our data provide a
molecular link between these pathways, and gives clues to their
mechanism of action as drivers of ccRCC. Furthermore, the func-
tional connection between super enhancer-driven transcriptional
programmes and core metabolic pathways may help explain the
stability of cell identity-defining molecular networks in cancer.
Results
KLF6 is associated with a super enhancer in ccRCC. Histone H3
lysine 27 acetylation (H3K27ac) marks active gene regulatory
elements26, which in some genomic loci cluster together to form
large domains or super enhancers characterized by particularly
high H3K27ac signal23. Several lines of evidence suggest that
super enhancers promote the expression of critical transcriptional
regulators in various biological contexts22,23. In order to identify
transcriptional networks that support ccRCC progression, we
analysed H3K27ac chromatin immunoprecipitation coupled with
high-throughput sequencing (ChIP-seq) data from several VHL
mutant ccRCC cell lines27 and looked for transcription factor-
associated super enhancers. We found that one of the strongest
super enhancers in ccRCC cells encompassed KLF6, a gene
encoding a zinc finger DNA-binding transcription factor
(Fig. 1a). Similarly, high H3K27ac signal was also observed in the
proximity of the KLF6 locus in ccRCC patient samples and
ccRCC xenografts (Fig. 1b). In line with the possibility that the
super enhancer regulates KLF6, we observed high and relatively
specific expression of KLF6 in ccRCC samples when compared to
other solid cancer types in the large TCGA cohort (Supplemen-
tary Fig. 1a). KLF6 expression was also higher in ccRCC samples
when compared to normal kidney tissue (Supplementary Fig. 1b),
and ccRCC cell lines, including highly metastatic derivatives28,
expressed high levels of KLF6 protein (Supplementary Fig. 1c).
KLF6 supports ccRCC fitness in vitro and in vivo. KLF6 can be
expressed as several differentially spliced variants (SV-1, SV-2
and SV-3), some of which have been linked to tumour
progression29,30. We analysed RNA-seq data from several ccRCC
cell lines to determine the expression level of the full-length KLF6
as well as the reported three KLF6 variants. Full-length KLF6
was the predominant isoform and we found little evidence for
the expression of the other variants (Supplementary Fig. 1d). To
test the biological relevance of KLF6, we inactivated KLF6 using
lentivirally delivered CRISPR-Cas9 in VHL mutant ccRCC cell
lines. We used cell lines derived from human tumours (UOK101
and RCC-MF) but also experimentally derived highly metastatic
subclones of human ccRCC cell lines (786-M1A and OS-LM1)28,
which recapitulate several important features of human ccRCC at
both phenotypic and molecular levels, including high metastatic
potential and relevant histology in xenograft assays28, in vivo
response to drug treatment7, mutational landscape31, and acti-
vation of genes that correlate with poor patient outcome in
clinical ccRCC data sets27,28. Two KLF6-targeting sgRNAs,
sgKLF6-4 and sgKLF6-5, were highly efficient in inducing
mutations at their predicted target regions (Supplementary
Fig. 2a), with corresponding KLF6 protein depletion in the
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-09116-x
2 NATURE COMMUNICATIONS |         (2019) 10:1152 | https://doi.org/10.1038/s41467-019-09116-x | www.nature.com/naturecommunications
CRISPR-Cas9-targeted cell pools (Supplementary Fig. 2b). The
proliferative capacity of the KLF6 depleted cell pools was then
assessed using a competitive proliferation assay (Fig. 1c). In all
four cell lines tested, KLF6 depletion led to impaired growth
(Fig. 1d). To confirm that the result was not confounded by the
fluorescent markers, the assay was also performed by swapping
the vector backbones. We observed consistent impaired growth in
the KLF6 depleted cells (Supplementary Fig. 2c). Reintroduction
of exogenous KLF6 mitigated the proliferative defect (Supple-
mentary Fig. 2d).
In some contexts, CRISPR-Cas9-targeted mutagenesis reduces
cell fitness independently of the target locus32. We, therefore,
validated our findings using lentivirally delivered CRISPR
interference (CRISPRi)33, a non-mutational method of KLF6
silencing that utilizes a catalytically inactive dCas9 fused with the
KRAB transcriptional repressor domain (Supplementary Fig. 2e).
Stable CRISPRi-mediated inhibition of KLF6 expression in a
pool of 786-M1A cells also resulted in impaired ccRCC cell
proliferation in vitro, and reintroduction of exogenous KLF6
rescued the phenotype (Fig. 1e, f). We then investigated the
phenotype of KLF6 inhibition in vivo. We injected pools of 786-
M1A and OS-LM1 cells in which KLF6 had been targeted using
CRISPR-Cas9 subcutaneously into immunocompromised mice
and followed tumour formation and growth over time. KLF6-
targeted cells formed smaller tumours when compared to control
cells (Fig. 2a, b and Supplementary Fig. 3a–c). Genetic analysis
revealed selection for the wildtype KLF6 gene in KLF6-targeted
tumours (Supplementary Fig. 3d) when compared to the same
cells in tissue culture (Supplementary Fig. 2a), indicating that the
tumours formed by KLF6-targeted cells consisted at least partially
of escaper cells. Similarly, an experimental lung colonization
















































































































































































































































Fig. 1 KLF6, a super enhancer-associated transcription factor, supports ccRCC growth in vitro. a A strong super enhancer, active in ccRCC cells, is proximal
to the KLF6 locus. b H3K27ac ChIP-seq signal at the large enhancer cluster in the proximity of the KLF6 locus in ccRCC cell lines, tumour xenografts and
clinical ccRCC samples. c Strategy for the competitive proliferation assay. d Competitive proliferation assay of KLF6-targeted VHL mutant ccRCC cells
(pools of lentivirally transduced CRISPR-Cas9 knock-out cells). The relative fraction of BFP+ KLF6-targeted and mCherry+ control cells, normalized to day
0. 786-M1A and OS-LM1 average of two technical replicates; UOK101 and RCC-MF average of three technical replicates. Two-tailed Student’s t-test.
e (Top) Competitive proliferation assay of the population of KLF6-targeted 786-M1A cells (lentivirally delivered CRISPRi). The relative fraction of iKLF6 and
NTC transduced cells, normalized to day 0, compared to untransduced cells. Average of three technical replicates. Two-tailed Student’s t-test. (Bottom)
Immunoblot showing KLF6 expression in the cells used in the competitive proliferation assay. f (Top) Competitive proliferation assay of KLF6-targeted
786-M1A cell pools (lentivirally delivered CRISPRi) transduced with exogenous KLF6. Relative fraction of iKLF6, iKLF6 with exogenous KLF6 or NTC
transduced cells, normalized to day 0, compared to untransduced cells. Average of three technical replicates. Two-tailed Student’s t-test. (Bottom)
Immunoblot showing KLF6 expression in the cells used in the competitive proliferation assay
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786-M1A cells in which KLF6 was silenced using CRISPRi
(Fig. 2c, d). These results demonstrate that KLF6 supports ccRCC
fitness in vitro and in vivo.
KLF6 activation by a robust super enhancer. Cancer-associated
super enhancers can be sensitive to perturbation24,34. To test
whether the KLF6 super enhancer locus was also sensitive to
perturbations in the activity of its constituent enhancers, we
employed a CRISPRi-based approach to inactivate several distinct
enhancers within the KLF6 super enhancer locus using five
sgRNA pairs in independent tandem constructs (iSE-1–iSE-5), a
method we have previously used for highly efficient and specific
targeting of distal enhancers27. Using p300 ChIP-seq data as a
guide27, we targeted the sgRNA constructs to the p300 peaks in
the valleys of H3K27ac signal, regions considered to be the target
sites for transcription factor binding. H3K27ac ChIP-seq con-
firmed efficient and specific targeting of individual regions within
this large cluster of enhancers (Fig. 3a). We did not observe clear
interdependencies between the different enhancers. We then
assessed KLF6 expression in the enhancer-targeted cells and
found that KLF6 levels were only subtly affected by the inhibition
of some of these enhancers (Supplementary Fig. 4a). Combina-
torial targeting of enhancer pairs showed additive effects, but
even then the expression of KLF6 remained fairly strong (Sup-
plementary Fig. 4b), whereas simultaneous targeting of all five
enhancers reduced KLF6 mRNA expression by ~60% (Fig. 3b).
We then used CRISPR-Cas9 to genetically remove a 113 kb seg-
ment of the super enhancer. In cell populations this resulted in
relatively modest downregulation of KLF6 (Supplementary
Fig. 4c), possibly reflecting heterogeneity in targeting efficiency.
We, therefore, isolated single cell-derived clones from this
population and performed PCR-based screening for the deletion
(Supplementary Fig. 4d). We identified a clone with a putative
homozygous deletion, a heterozygous deletion and no deletion for
further analyses. In line with the PCR data, H3K27ac ChIP-seq
confirmed the reduction in signal in the heterozygous clone, while
no signal from the targeted region was detected in the clone
carrying the homozygous deletion (Fig. 3c). KLF6 expression was
also progressively reduced in the clones carrying super enhancer
deletions (Fig. 3d), with homozygous deletion resulting in a
similar effect to that seen in the cells in which five constituent
enhancer regions were simultaneously targeted by CRISPRi
(Fig. 3b). RNA-seq-based analysis comparing the clone with a
homozygous deletion to the clone with no deletion revealed that
KLF6 was the most significantly downregulated gene within the 5
Mb genomic region flanking the 113 kb deletion, supporting the
possibility that KLF6 was one of the main targets of this super
enhancer (Fig. 3e). These observations suggest that KLF6 is
regulated by a robust super enhancer, which tolerates CRISPRi-
mediated perturbation of the individual constituent enhancers.
However, simultaneous inactivation of several constituent
enhancers, as well as a large deletion of the super enhancer,
resulted in significant KLF6 downregulation, supporting the idea
that this large enhancer cluster functions in a modular manner to
drive KLF6 expression in ccRCC.
KLF6 interacts with the HIF2A pathway in ccRCC. Given the
prominent role of HIF2A in ccRCC pathogenesis, we next tested
whether the VHL-HIF2A axis modulated KLF6 expression. First,
































































































































Fig. 2 KLF6 supports ccRCC growth and metastatic colonization in vivo. a, b Subcutaneous tumour growth of KLF6-targeted 786-M1A (a) and OS-LM1 (b)
cells. Pools of lentivirally transduced CRISPR-Cas9 knock-out cells. 786-M1A, N= 10 tumours/group. OS-LM1, N= 14 tumours for sgKLF6-4 and sgKLF6-5
groups, N= 12 tumours for the control group. Error bars, SEM. Two-tailed Mann–Whitney U-test. c (Left) Average normalized lung photon flux of
intravenously inoculated KLF6-targeted or control 786-M1A cells (lentivirally delivered CRISPRi). N= 5 mice/group. Error bars, SEM. Two-tailed
Mann–Whitney U-test. (Right) Representative bioluminescence images and histological lung sections stained with human vimentin. Scale bar, 5 mm.
d Quantification of the human vimentin-stained lung metastatic foci from the experiment in c. Two-tailed Mann–Whitney U-test
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between HIF2A and KLF6 expression, similar to that seen for the
well-characterized HIF2A target gene CCND1 (Fig. 4a). Alongside
CCND1 and CXCR4, KLF6mRNA expression was reduced in VHL-
reintroduced 786-M1A and OS-LM1 cells (Fig. 4b). KLF6 down-
regulation was also observed at the protein level in both cell lines
(Fig. 4c). HIF2A has been recently linked to the maintenance of
ccRCC super enhancers35. We, therefore, used ChIP-seq to test the
effects of VHL reintroduction, and the consequent loss of HIF2A, to
the H3K27ac patterns of the KLF6 super enhancer locus. We
observed a reduction in H3K27ac signal at one of the enhancer
regions downstream of the KLF6 locus in 786-M1A and OS-LM1
cells (Fig. 4d). Analysis of HIF2A ChIP-seq data confirmed that
HIF2A bound the same enhancer region (Fig. 4e and Supplemen-
tary Fig. 5a). We also observed reduced HIF2A binding at this
locus upon VHL reintroduction by ChIP-qPCR in 786-M1A and
OS-LM1 cells (Supplementary Fig. 5b). However, consistent with
the previous observation that this particular super enhancer is
insensitive to perturbation (Fig. 3a), the general H3K27ac pattern
remained mostly unchanged (Fig. 4d). Using the CRISPRi
approach, we then targeted two putative HIF2A binding sites within
this region. This resulted in ~ 40% reduction in KLF6 expression
(Fig. 4f), an effect of a similar magnitude to that caused by VHL
reintroduction (Fig. 4b). Collectively, these data suggest that HIF2A
supports KLF6 expression by acting through the large KLF6 super
enhancer, potentially explaining the relatively high KLF6 levels in
ccRCC when compared to other tumour types (Supplementary
Fig. 1a).
We then performed transcriptomic analysis by RNA-seq on
KLF6 CRISPRi and control 786-M1A cells. As expected, the most
significantly downregulated gene in the KLF6-targeted cells was
KLF6 itself (Fig. 5a and Supplementary Data 1). In agreement
with the finding that KLF6 operated at least partially downstream
of the HIF2A pathway, gene set enrichment analysis on the
differentially expressed genes revealed a highly significant
association between KLF6-depletion and downregulation of the
canonical hypoxia-response gene set (Supplementary Fig. 6a). To
study this further, we expressed exogenous KLF6 in the VHL-
reintroduced 786-M1A cells and assessed the expression of the
HIF2A downstream targets CCND1, VEGFA and BHLHE40. As
expected, the expression of these genes was downregulated in the
VHL-reintroduced cells. Reintroduction of KLF6 restored
BHLHE40 expression whereas CCND1 and VEGFA expression
remained low (Supplementary Fig. 6b). KLF6-dependent reversal
of the negative effect of VHL reintroduction on BHLHE40
expression was also observed in OS-LM1 cells (Supplementary
Fig. 6c). In agreement, BHLHE40 expression was attenuated in
KLF6-depleted cells and KLF6 reintroduction was able to restore
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Fig. 3 KLF6 is regulated by a robust super enhancer. a H3K27ac ChIP-seq signal in the KLF6 locus. The target region for CRISPRi-based enhancer
inactivation indicated by dashed boxes. b KLF6 mRNA expression in the pool of 786-M1A cells with simultaneous CRISPRi-mediated inactivation of the five
enhancer regions shown in a. Average of four experiments. Error bars, SEM. c H3K27ac ChIP-seq signal in the KLF6 locus in clones with no deletion (top),
heterozygous deletion (middle), and homozygous deletion (bottom). d KLF6 expression in the single cell-derived clones shown in c. Average of three
experiments. Error bars, SEM. e Expression of genes located within a 5Mb window flanking the 113 kb deletion in the super enhancer region. Clone Del
SE 3-19 compared to clone Del SE 3-9 by RNA-seq, N= 4 for both samples. The blue bar indicates the location of the 113 kb deletion
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the HIF2A transcriptional programme in ccRCC is also supported
by its downstream transcriptional effector KLF6. Even though
HIF2A regulates KLF6 expression, it remains possible that the
downregulation in BHLHE40 expression upon VHL restoration is
not dependent on reduced KLF6 expression; the data are also
compatible with a model in which KLF6 and HIF2A regulate
BHLHE40 expression independently. However, the data show
functional interaction between the HIF2A and KLF6 pathways.
This observation is similar to that described for PBRM1, the loss
of which has been linked to alterations in the transcriptomic
consequences of VHL loss in ccRCC36. Multiple independent pro-
tumorigenic factors thus seem to modulate the downstream
effects of the VHL-HIF2A tumour driver pathway in ccRCC.
KLF6 maintains lipid homeostasis in ccRCC. Despite KLF6
being a component of the HIF2A pathway, the phenotype of
KLF6-depleted cells was not similar to VHL-reintroduced ccRCC
cells, which normally do not show a proliferative defect under
standard tissue culture conditions4. Hence, we performed an
unbiased pathway analysis on the RNA-seq data to identify
potential KLF6 downstream effectors that could explain the
reduced fitness of the KLF6-depleted cells. Pathways related to
lipid homeostasis such as cholesterol and triacylglycerol bio-
synthesis were among the topmost significantly altered pathways
with several key genes being downregulated in the KLF6 knock-
down cells (Fig. 5b). Gene set enrichment analysis also revealed a
significant association between genes downregulated upon KLF6
inhibition and those involved in cholesterol homeostasis (Fig. 5c).
A targeted analysis of the key genes that participate in each step
of triacylglycerol and cholesterol biosynthesis pathways revealed
that many of these genes were downregulated in the KLF6
knockdown cells (Supplementary Fig. 7a). In addition, two critical
transcription factors, SREBF1 and SREBF2, that support the
expression of lipid homeostasis genes, were also downregulated
by KLF6 inhibition. Moreover, analysis of published ChIP-seq
data sets37,38 revealed that the regulatory regions of many of these
genes were directly bound by SREBF1 and/or SREBF2 (Supple-
mentary Fig. 7a). qRT-PCR analyses validated the reduced
expression of SREBF1 and SREBF2 as well as SCD and LSS, two
enzymes involved in the key intermediate steps of triacylglycerol
and cholesterol biosynthesis pathways, respectively (Supplemen-
tary Fig. 7b). Furthermore, we observed a reduction in the total
cholesterol level in the KLF6-depleted cells (Fig. 5d). To test the
contribution of lipid homeostasis perturbation on the phenotype
of KLF6 inhibited cells, we combinatorially inhibited SREBF1 and
SREBF2 expression in 786-M1A cells by CRISPRi (Supplementary
Fig. 8a). In line with the effects of KLF6 inhibition, this led to a
reduction in total cellular cholesterol levels (Fig. 5e) and impaired
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Fig. 4 HIF2A modulates KLF6 expression in ccRCC. a KLF6 (red) and CCND1 (blue) expression correlates with HIF2A expression in the clinical TCGA ccRCC
data set. Pearson’s correlation coefficient. b Expression of KLF6 and the HIF2A downstream targets, CXCR4 and CCND1, as measured by qRT-PCR, in the
HA-VHL reintroduced 786-M1A and OS-LM1 cells. Average of three experiments. Error bars, SEM. c KLF6, HIF2A and VHL immunoblot of cells transduced
with HA-VHL or empty vector. Representative of three experiments for 786-M1A and two for OS-LM1 cells. d H3K27ac ChIP-seq signal of 786-M1A and
OS-LM1 cells transduced with empty vector or HA-VHL. A region significantly altered in both HA-VHL reintroduced cells when compared to the empty
vector control highlighted by the dashed box. e A close up of the region highlighted in d for 786-M1A cells together with HIF2A ChIP-seq signal in the
parental 786-M1A cells. f KLF6 mRNA expression level in a population of 786-M1A cells in which two putative HIF2A binding sites were targeted using
CRISPRi. Average of three experiments. Error bars, SEM
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SREBF1 and SREBF2 inhibitor39, also reduced the proliferation of
786-M1A cells in a dose-dependent manner (Fig. 5g). Similar
effects were observed with simvastatin, an inhibitor of HMG-CoA
reductase, a critical enzyme in the cholesterol biosynthetic path-
way (Supplementary Fig. 8b). Collectively, these data suggest that
KLF6 promotes ccRCC fitness by supporting the expression of
lipid metabolism effectors.
Co-regulation of lipid homeostasis by KLF6 and mTORC1. The
mTORC1 complex modulates lipid biosynthesis via regulation of
SREBF1 and SREBF2 expression and activity40–42. Thus, our
observation that KLF6 regulated SREBF1 and SREBF2 expression,
but also the expression of their downstream targets, was com-
patible with at least two mutually non-exclusive possibilities.
First, KLF6 could positively regulate SREBF1 and SREBF2 mRNA
expression, which would have secondary effects on their down-
stream targets. Alternatively, KLF6 could positively regulate
mTOR activity, which would translate into increased SREBF1 and
SREBF2 levels and activity. To distinguish between these two
possibilities, we first tested whether mTOR regulated SREBF1 and
SREBF2 in our systems. As expected, the mTOR antagonist torin
1 strongly inhibited mTORC1 activity, as indicated by the
reduction of the phosphorylated forms of p70 S6 kinase (P-p70 S6
kinase) and ribosomal S6 (P-S6) (Supplementary Fig. 9a). This
also led to decreased expression of the active forms of SREBF1
and SREBF2 (Supplementary Fig. 9a), and reduced total choles-
terol (Supplementary Fig. 9b). Xenograft analysis showed that the
mTOR pathway activity supported ccRCC growth in vivo (Sup-
plementary Fig. 9c). In line with reduced SREBF1 and SREBF2
activity, the expression of SCD and LSS was reduced in torin 1-
treated cells. Additionally, we observed a reduction in SREBF1
mRNA (Supplementary Fig. 9d). However, in contrast to the
effects seen upon KLF6 inhibition (Supplementary Fig. 7b), torin
1 treatment led to an increase in SREBF2 mRNA expression
(Supplementary Fig. 9d). Thus, while mTOR inhibition phe-
nocopied the effects of KLF6 depletion at the level of SREBF1 and
SREBF2 downstream targets, KLF6 inhibition additionally resul-
ted in a reduction of SREBF2 mRNA expression, suggesting
possible direct effects of KLF6.
To test the role of KLF6 as a direct regulator of lipid
metabolism genes, we then performed ChIP-seq on flag-tagged
KLF6 that was introduced into KLF6-depleted cells. qRT-PCR
analysis confirmed that the tagged KLF6 was functional and it
could rescue the expression of a lipid metabolism gene
(Supplementary Fig. 10a). We identified >11,000 KLF6 peaks,
distributed across different gene regulatory regions, most
prominently at promoters, with an enrichment for a motif bound
by members of the KLF family (Supplementary Fig. 10b).
Importantly, the proximal regulatory regions of SREBF1, SREBF2,
SCD, and LSS contained KLF6 peaks (Supplementary Fig. 10c–f).
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Fig. 5 KLF6-dependent lipid homeostasis pathways promote ccRCC growth. a Volcano plot showing the differentially expressed genes in KLF6-targeted
versus control 786-M1A cells (lentivirally delivered CRISPRi). Blue and red circles represent genes that were significantly upregulated and downregulated,
respectively, in KLF6-targeted cells. b Most significantly deregulated pathways upon KLF6 inhibition as determined by Ingenuity Pathway Analysis.
Highlighted in red are pathways involved in lipid homeostasis. Heatmap (right) shows significant downregulation of several key genes in the cholesterol
biosynthesis pathway. Blue, low expression; red, high expression. c Gene set enrichment analysis shows downregulation of cholesterol homeostasis-related
genes in KLF6-depleted cells. Blue, low correlation; red, high correlation. d Total cholesterol level in KLF6-targeted 786-M1A CRISPRi cells. Average of three
experiments. Error bars, SEM. Two-tailed Student’s t-test. e Total cholesterol level in SREBF1 and SREBF2-targeted 786-M1A CRISPRi cells. Average of
three experiments. Error bars, SEM. Two-tailed Student’s t-test. f Competitive proliferation assay of SREBF1 and SREBF2-targeted 786-M1A CRISPRi cells.
The relative fraction of iSREBF1/2 double targeted cells and NTC transduced cells, normalized to day 0, compared to untransduced cells. Average of three
technical replicates. Two-tailed Student’s t-test. g Proliferation of 786-M1A cells treated with either vehicle or indicated concentrations of fatostatin.
Average of six technical replicates. Two-tailed Student’s t-test
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contributing to the lipid metabolic phenotype of KLF6-depleted
cells. In line with this possibility, mTORC1 activity was reduced
in KLF6-inhibited cells (Fig. 6a, b). Collectively, these data
demonstrate that KLF6 supports lipid homeostasis at two levels.
First, KLF6 directly regulates the expression of lipid metabolism
genes. Second, KLF6 promotes mTOR signalling which enhances
the activation of lipid metabolism through SREBF1 and SREBF2.
KLF6 supports mTOR activity via enhanced PDGFB expres-
sion. Given that KLF6 is a transcription factor with no previously
characterized link to the mTOR pathway, we investigated whether
KLF6 transcriptionally activated a known mTOR agonist. RNA-
seq data for downregulated genes in the KLF6-depleted cells
highlighted platelet derived growth factor subunit B (PDGFB) as a
possible candidate. PDGFB can activate the mTOR pathway and
previous data suggests that it also modulates SREBF1 and
SREBF2 activity43. The qRT-PCR analysis confirmed that PDGFB
was downregulated in KLF6-targeted cells (Fig. 6c and Supple-
mentary Fig. 11a–b) and reintroduction of KLF6 into KLF6
knockdown cells was able to rescue PDGFB expression (Supple-
mentary Fig. 12a–b). Analysis of KLF6 ChIP-seq data showed
that KLF6 binds to the proximal regulatory regions of PDGFB, a
finding confirmed by ChIP-qPCR analysis (Supplementary
Fig. 12c–d). Supporting the clinical relevance of our finding,


































































































































































































































































































a b c d
e f g
h
Fig. 6 KLF6 modulates mTORC1 activity via transcriptional regulation of PDGFB expression. a mTORC1 activity in KLF6-targeted 786-M1A CRISPRi cells as
determined by immunoblotting. Representative of three experiments. b mTORC1 activity in the pool of KLF6-targeted OS-LM1 and UOK101 CRISPRi cells.
Representative of two and three experiments are shown for OS-LM1 and UOK101 cells, respectively. c PDGFB expression in KLF6-targeted 786-M1A
CRISPRi cells as measured by qRT-PCR. Average of three experiments. Error bars, SEM. d PDGFB expression (RSEM normalized counts) in clinical ccRCC
samples with either high (top 50%) or low (bottom 50%) KLF6 expression. TCGA ccRCC cohort. Mann–Whitney U-test. Boxplot represents median and
25th and 75th percentiles, whiskers 1.5 times the interquartile range. e PDGFB target gene expression (sum of Z-scores) in clinical ccRCC samples with
either high (top 50%) or low (bottom 50%) KLF6 expression. TCGA ccRCC cohort. Mann–Whitney U-test. Boxplot represents median and 25th and 75th
percentiles, whiskers 1.5 times the interquartile range. f mTORC1 activity in PDGFB-targeted 786-M1A CRISPRi cells as determined by immunoblotting.
Representative of two experiments. g, h mTORC1 activity in KLF6-targeted 786-M1A CRISPRi cells supplemented with either human recombinant PDGFB
(10 ng/ml) or vehicle control for 1 h. Representative of two experiments. Quantification of immunoblot bands shown on the right
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expressed higher levels of PDGFB in the TCGA data set (Fig. 6d).
Furthermore, gene set enrichment analysis demonstrated a sig-
nificant downregulation of a previously derived PDGFB-
responsive gene signature43 in KLF6-depleted cells (Supplemen-
tary Fig. 12e). The PDGFB response signature was also more
active in patient samples with higher KLF6 expression in the
ccRCC TCGA data set (Fig. 6e). Finally, to directly test the role of
PDGFB as a regulator of mTOR in our systems, we targeted
PDGFB by CRISPRi (Supplementary Fig. 12f) and assessed the
levels of P-p70 S6 kinase and P-S6. Knocking down PDGFB
inhibited mTORC1 activity (Fig. 6f), phenocopying the effects of
KLF6 inhibition (Fig. 6a). Conversely, supplementing KLF6-tar-
geted cells with recombinant human PDGFB re-activated mTOR
signalling (Fig. 6g, h). This suggested that KLF6 supports mTOR
signalling by directly regulating the expression of PDGFB.
Discussion
We report the identification of a cellular signalling loop that links
the transcription factor KLF6 to lipid metabolic activity,
enhanced tumour growth and metastatic colonization in ccRCC.
KLF6 expression is supported by a large super enhancer that is
partially activated by the ccRCC-initiating VHL-HIF2A pathway.
The high prevalence of VHL mutations and consequent HIF2A
stabilization could thus explain the relatively high KLF6 mRNA
levels observed in human ccRCCs. Transcriptional profiling
revealed a prominent lipid metabolism defect in KLF6-targeted
ccRCC cells. We find that KLF6 has a dual effect on lipid
homeostasis as a regulator of both the transcription of lipid
metabolism genes, and the activation of SREBF1 and SREBF2
through the PDGFB-mTOR axis (Fig. 7). These results suggest a
mechanism for the prevalent mTOR activation in human ccRCC.
Moreover, the links between super enhancer-driven transcrip-
tional networks and the activity of essential metabolic pathways
may explain the stability of cell identity-defining transcriptional
programmes in cancer.
Previous reports have suggested that large cancer-associated
enhancer clusters or super enhancers may be particularly sensitive
to perturbations, making them putative therapeutic targets21. We
characterized one of the strongest super enhancer loci in ccRCC
cells by targeted inhibition of several of its constituent enhancers
using CRISPRi and by deleting a large 113 kb segment of the
super enhancer using CRISPR-Cas9 gene editing. Only some of
the constituent enhancers were individually essential for full KLF6
expression. Simultaneous targeting of two enhancers more
strongly reduced KLF6 expression, but even then the effects were
relatively subtle. Further reduction in KLF6 was observed when
all five enhancers were inactivated simultaneously. Finally, even
in the cells with a large deletion that covered several individual
enhancers, KLF6 mRNA level was reduced by only ~65%. KLF6
expression is thus regulated by a robust super enhancer which is
insensitive to alterations in the activity of many of its constituent
enhancers. Such redundancy is well-aligned with the fact that
most biological processes and developmental transcriptional
programmes are insensitive to environmental and other incoming
variation44. It is interesting to note, however, that VHL restora-
tion and the consequent inactivation of HIF2A was able to reduce
KLF6 expression by ~50%. Taken together, our analysis of the
upstream regulation of KLF6 expression suggests that the iden-
tification of relevant gene regulatory elements simply based on
chromatin profiling is challenging45 and that functional analysis
of enhancer function is needed. Also, therapeutic targeting of
transcriptional addictions in cancer may at least in some contexts
be more complicated than what has been suggested by some
reports24.
KLF6 has been described to have both growth suppressive and
supportive functions in different cancers46–48. Large-scale cancer
genome re-sequencing efforts suggest that KLF6 is rarely inacti-
vated via genetic alterations49,50. In ccRCC specifically, the large
TCGA cohort of 448 cases reports no point mutations and only
one tumour with a deep deletion of KLF6. In this particular case,
KLF6 is lost together with several other genes on chromosome
10p, suggesting that the alteration is not specifically targeting
KLF6. On the other hand, the expression and chromatin altera-
tion patterns we observe in human ccRCCs and cell lines are
supportive of a pro-tumorigenic role for KLF6. In contrast to
breast cancer where a KLF6 splice variant promotes metastatic
progression47, our results suggest that full-length KLF6, down-
stream of a robust super enhancer, promotes ccRCC growth
















Fig. 7 Model: A robust super enhancer, partially activated by HIF2A, supports KLF6 expression in ccRCC. KLF6 promotes the expression of PDGFB, leading
to the activation of mTORC1 and the downstream regulators of lipid metabolism, SREBF1 and SREBF2. Additionally, KLF6 supports the expression of SREBF2,
and possibly also SREBF1 and their downstream targets, independently of mTORC1. Collectively these two pathways enhance lipid metabolism, leading to
increased ccRCC growth
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regulates the expression of lipid homeostasis genes directly, but it
also enhances the activation of SREBF1 and SREBF2 by sup-
porting the expression of PDGFB, a prominent activator of the
mTOR pathway. Genetic and pharmacological inhibition of
SREBF1 and SREBF2 activity also reduced ccRCC proliferation,
suggesting that effects on lipid metabolism explain at least par-
tially the phenotypic consequences of KLF6 depletion, although
our results do not exclude the possibility that KLF6 promotes
ccRCC growth through other mechanisms as well. However, we
do not understand the reasons for the differences between our
results and those of Gao et al. who have recently reported a
tumour suppressive role for KLF6 in ccRCC46. Gao et al.
also report that KLF6 represses the expression of E2F1, an effect
we do not observe (Supplementary Fig. 13a).
Two genes, CPT1A and PLIN2, have recently been implicated
in HIF-dependent lipid accumulation in ccRCC51,52. CPT1A is
repressed by HIF1A and HIF2A, consequently leading to lipid
droplet formation and enhanced ccRCC growth due to reduced
fatty acid transport into the mitochondria. PLIN2, encoding a
lipid droplet coat protein, is positively regulated by HIF2A, and it
promotes lipid droplet accumulation and ccRCC fitness. Based on
our RNA-seq data, the expression of both CPT1A and PLIN2 is
downregulated upon KLF6 depletion. This suggests that in
addition to regulating the SREBF1 and SREBF2 pathways, KLF6-
dependent effects on ccRCC lipid metabolism may also involve
PLIN2 and CPT1A. However, as VHL reintroduction increases
CPT1A expression but decreases KLF6 expression, and
KLF6 supports CPT1A expression (Supplementary Fig. 13b), it
seems unlikely that the pro-tumorigenic effects of KLF6 are
directly caused by modulation of CPT1A activity through the
mechanism recently described by Du et al.51. Further work is thus
needed for a comprehensive understanding of how different
mediators of lipid metabolic phenotypes contribute to ccRCC.
The mTOR pathway can be activated by multiple different
signals53. We find that in ccRCC cells, mTOR activity is sup-
ported by PDGFB. Given that the 786-M1A cells carry a homo-
zygous truncating mutation in PTEN31, our data suggest that
upstream PDGFR activation is required for mTOR activation in
ccRCC cells even when PTEN is lost. Interestingly, our results
functionally link two approved therapeutic targets in ccRCC, the
PDGFR and mTOR pathways, suggesting a molecular explana-
tion for the favourable effects of an mTOR/PDGFR combinatorial
treatment approach in ccRCC54. In a phase II randomised trial of
everolimus and lenvatinib (an inhibitor of both PDGFRA and
PDGFRB55) in combination versus the drugs as monotherapy for
patients with metastatic renal cell carcinoma who have progressed
after one previous VEGF-targeted therapy, lenvatinib plus ever-
olimus were found to act synergistically to provide a progression-
free survival (PFS) benefit over either drug alone, although a
significant difference was seen only over everolimus (median PFS
14·6 months vs 5·5 months)54. However, although grade 3 and 4
events occurred in fewer patients allocated single-agent ever-
olimus (50%) compared to lenvatinib plus everolimus (71%),
there was greater toxicity in those patients assigned lenvatinib
alone (79%); overall, the toxicity was manageable with dose
reductions.
In conclusion, we describe molecular signalling network that
links the super enhancer-associated transcription factor KLF6 to
lipid metabolism and enhanced mTOR activity in ccRCC. Our
experimental analyses of the super enhancer upstream of KLF6
demonstrate the robustness of some cancer-associated super
enhancers. This may complicate the usage of therapeutic agents
that aim at super enhancer inactivation in cancer. Finally, the link
between super enhancer-associated programmes and core meta-
bolic pathways may provide clues to the mechanisms that
maintain cell identity-defining transcriptional networks in cancer.
Methods
Cell lines and reagents. The human RCC cell lines 786-O, 786-M1A, OS-RC2,
OS-LM1, RCC-MF were obtained from J. Massagué (MSKCC, New York, NY) in
2014. The UOK101 cell line was obtained from Marston Linehan (the UOB Tumor
Cell Line Repository, National Cancer Institute, Bethesda, MD) in 2014. 786-M1A
and OS-LM1 are metastatic derivatives of 786-O and OS-RC2 cells, respectively28.
The A549 lung cancer cell line was obtained from C. Martins (MRC Cancer Unit)
in 2017. The identity of all cell lines was confirmed by STR analysis. All cells were
confirmed to be mycoplasma negative by using the MycoAlertTM Mycoplasma
Detection Kit (Lonza, LT07-318). At the time of the study, none of the cell lines in
this paper were listed in the database of commonly misidentified cell lines main-
tained by ICLAC. All RCC cell lines were cultured in RPMI-1640 medium (Sigma)
supplemented with 10% FBS, penicillin (100 UmL−1) and streptomycin (μg mL
−1). For lentivirus production, HEK293T cells were used and cultured in DMEM
(Invitrogen), supplemented with 10% FBS, penicillin (100 UmL−1) and strepto-
mycin (μg mL−1).
Doxycycline-inducible Cas9, pCW-Cas9 was a gift from Eric Lander and David
Sabatini (Addgene plasmid #50661)56. LentiCas9-Blast was a gift from Feng Zhang
(Addgene plasmid #52962)57. pHR-SFFV-KRAB-dCas9-P2A-mCherry was a gift
from Jonathan Weissman (Addgene plasmid #60954)58. pKLV-U6-gRNA(BbsI)-
PGKpuro2ABFP, was a gift from Kosuke Yusa (Addgene plasmid #50946)59. This
vector was modified to generate the following plasmid variants: (i) pKLV-U6-
gRNA(BbsI)-PGKhygro2ABFP, (ii) pKLV-U6-gRNA(BbsI)-PGKhygro2AmCherry
(iii) pKLV-U6-gRNA(BbsI)-PGKhygro2AeGFP. pLVX-Puro (Clontech #632164)
was used to express the exogenous cDNA constructs. For lentivirus production,
packaging plasmids, psPAX2 (Addgene plasmid #12260) and pMD2.G (Addgene
plasmid #122259) were gifts from Didier Trono. All sgRNA constructs and primers
used in this study were purchased from Sigma-Aldrich and the sgRNA sequences
are available in Supplementary Table 1 and 2. Everolimus was purchased from
APExBIO (A8169). Fatostatin (F8932), simvastatin (S6196), propylene glycol
(W294004) and Tween-80 (P4780) were purchased from Sigma-Aldrich.
Lentiviral transduction. HEK293T cells were transfected with a mixture of the
lentiviral transfer plasmid of interest, psPAX2 and pMD2.G using FuGENE 6
transfection reagent (Promega E269A). Media containing the lentivirus was col-
lected 48–72 h post-transfection and filtered through a 0.45 μM PVDG sterile filter.
Cells were transduced with the lentiviral supernatant in the presence of 8 µg/mL
Polybrene (Millipore).
Chromatin immunoprecipitation. Sub-confluent cells were trypsinized and
crosslinked with 1% formaldehyde-supplemented media for 10 min. The reaction
was quenched with 0.125M glycine for 5 min and washed with PBS twice. The cells
were either pelleted and stored at −80 oC, or subjected to immunoprecipitation.
For IP, protein A/G magnetic beads (Thermo, 26162) were first equilibrated by
washing the beads with 0.5% BSA in PBS three times. The beads were then
incubated with antibodies in 0.5% BSA in PBS at 4 oC while rotating for a mini-
mum of 4 h. The following antibodies were used: H3K27ac (Abcam, ab4729, 5 µg),
monoclonal FLAG (Sigma-Aldrich, F1804, 30 µg), HIF2A (Novus Biologicals,
NB100-122, 30 µg) and rabbit polyclonal IgG (Abcam, ab27478, 5 µg). The cross-
linked cells were resuspended and dounced in lysis buffer (20 mM Tris-HCl pH 8.0,
150 mM NaCl, 2 mM EDTA pH 8.0, 0.1% SDS and 1% Triton X-100), followed by
sonication using the Bioruptor (Diagenode) for 14 cycles, 30” on/30” off. The
lysates were spun down at 4 oC for 20 min at 14,000 rpm. The supernatants were
added onto the antibody-conjugated magnetic beads and incubated overnight at 4
oC while rotating. On the following day, the beads were washed three times with
low salt buffer (50 mM HEPES pH 7.5, 140 mM NaCl, 1% Triton) and once with
high salt buffer (50 mM HEPES pH 7.5, 500 mM NaCl, 1% Triton). DNA bound to
the antibody-conjugated beads was eluted with elution buffer (50 mM NaHCO3,
1% SDS) and de-crosslinked by shaking at 1000 rpm for 3 h at 65 °C. De-
crosslinked DNA was purified using the QuickClean II PCR Extraction Kit
(Genescript L00419-100) according to the manufacturer’s recommendations.
ChIP-seq library preparation. Purified ChIP DNA was subjected to Illumina
sequencing. Sequencing libraries were prepared using the KAPA Hyper Prep Kit
(KR0961) according to the manufacturer’s recommendations. Adapter-ligated
libraries were size-selected using Agencourt AmPure XP beads (Beckman Coulter,
A63880) to obtain fragments of 150–350 bp. Size-selected fragments were amplified
for 15 cycles using the KAPA HiFi HotStart Ready mix and the amplified libraries
were pooled in equimolar concentration for sequencing.
RNA-seq. Total RNA was extracted from sub-confluent cells in four replicates
using the RNeasy Mini Kit (Qiagen 74104) according to the manufacturer’s pro-
tocols. RNA concentration and quality were assessed with the Agilent RNA Nano
6000 kit (Agilent 5067-1511) on Agilent Bioanalyzer 2100 instrument. RNA-seq
libraries were prepared using the SENSE mRNA-Seq Library Prep Kit V2 (Lexo-
gen) following the manufacturer’s recommendations with 1 μg of total RNA as the
starting material. The size and quality of the final library products were assessed
using the Agilent High Sensitivity DNA Kit (Agilent 5067-4626). Library con-
centration was determined using the KAPA Library Quantification Kit (KR0405).
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Libraries were pooled in equimolar concentrations and subjected to Illumina
sequencing.
ChIP-seq and RNA-seq data analysis. ChIP-seq and RNA-seq sequencing were
performed on Illumina HiSeq HiSeq 4000 systems using 50 bp single-end runs.
Raw ChIP-seq sequencing reads were aligned to hg38 using bowtie260 and the
resulting sam files were converted into sorted bam files using samtools61. Peaks
were called using MACS262. RNA-seq sequencing reads were aligned to hg38 using
RSEM63 and bowtie2 with default settings. Gene set enrichment analysis (GSEA), a
computational method that determines whether an ‘a priori’ defined set of genes
demonstrates statistically significant, concordant differences between two biological
states, was performed using the gene expression data64. The GSEA software (ver-
sion 2-2.2.2) and Molecular Signature Database (MSigDB) (version 6.0) (http://
www.broad.mit.edu/gsea/) were used together with gene lists ranked by normalized
RNA-seq counts (CPMs). Normalized enrichment score (NES) and false discovery
rate (FDR) (p >= 0.25) were computed and used to quantify the magnitude of
enrichment and statistical significance, respectively. Pathway analyses of RNA-seq
data were performed with Ingenuity Pathway Analysis (IPA) software. (QIAGEN
Inc., https://www.qiagenbioinformatics.com/products/ingenuitypathway-analysis).
The fatty acid and cholesterol biosynthesis pathways were assembled using infor-
mation integration from a number of pathway databases (KEGG, Reactome,
Wikipathways, and Ingenuity Pathway Analysis) and pathway maps65–67. SREBF1/
2 targets were identified using the TRRUST database37 and the Harmonizome
resource38. Publicly available SREBF1/2 ChIP-seq data sets were collected from
NCBI GEO and SRA databases (SRP007993, SRP028819, SRP097662, SRP012412).
Fastq files were aligned using Bowtie2 (version 2.3.4.3) to the hg38 reference
genome from UCSC genome database and peaks were called using MACS2 (ver-
sion 2.1.0). Peaks from a consensus peak set (peaks detected in at least two sam-
ples) were annotated to genes if they were maximum 2.5 kb away from the gene
promoter, or on the gene body and had overlaps with TSSs identified by the
FANTOM project68 using the ChIPpeakAnno R/Bioconductor package69.
Human samples. The ccRCC tumour samples for ChIP-seq analyses have been
previously reported27. They were collected from nephrectomy specimens in
accordance with the Declaration of Helsinki. Patients were recruited for tissue
donation by providing written consent and after study approval from an Institution
Review Board (NRES Committee East of England-Cambridge Central, NHS Health
Research Authority; REC 03/018).
Animal studies. All animal experiments were performed in accordance with
protocols approved by the Home Office (UK) and the University of Cambridge
Animal Welfare and Ethical Review Body (PPL 70/7990). For subcutaneous
tumour growth assay, cells were pelleted and resuspended in PBS/Matrigel Matrix
(BD) mix at 1:1 ratio. 1 × 105 cells in 100 µL solution were injected into each flank
of 5–8 weeks old athymic male nude mice (Charles River Laboratories). Tumour
growth was monitored by IVIS bioluminescence imaging (Perkin Elmer) and
calliper measurement. Tumour volume (V) was calculated using the equation V=
(length × width2) × 0.5. For the lung colonization assay, cells were pelleted and
resuspended in 1× sterile PBS. 3 × 105 cells in 100 µL solution were injected into the
lateral tail vein of 5–7 weeks old NOD/SCID mice (Charles River Laboratories),
followed by bioluminescence imaging. At the end of the assay, lungs were extracted
and processed for immunohistochemistry. For the in vivo everolimus experiment,
500,000 cells were subcutaneously injected into 6 week-old athymic nude male
mice. After the tumours became palpable, mice were separated into two groups
with equal average tumour size and treated orally with either everolimus (5 mg/kg/
daily) or vehicle (30% propylene glycol and 5% Tween-80 in sterile water) for
3 weeks. Tumour growth was monitored by calliper measurement.
Histology and immunohistochemistry. Lungs were harvested from euthanized
mice and fixed in 10% formalin overnight. The formalin-fixed samples were sent to
the Cambridge University Hospital Human Research Tissue Bank for paraffin-
embedding and sectioning. Human vimentin (Cell Signaling Technology; Cat.
5741, 1:100) staining was performed in a Bond-Max instrument (Leica) using Bond
Polymer Refine Detection reagents (Leica) according to the manufacturer’s pro-
tocol (IHC Protocol F).
In vitro competitive proliferation assay. For CRISPR-Cas9 mutagenesis com-
petitive proliferation assay, control and targeted cells which carried different
fluorescent markers (BFP+ or mCherry+) were mixed at a 1:1 ratio and plated onto
6-wells plates. The percentage of each cell population was analysed at T= 0 and at
multiple time points throughout the assays by flow cytometry on LSR Fortessa (BD
Biosciences). The following gating approach was used: FSC-A, FSC-H, SSC-A to
select for live and single cells, and then mCherry (561 nm/610 nm) and BFP (383
nm/445 nm) channels for discriminating between the two cell populations. Similar
strategy was employed for the CRISPRi competitive proliferation assay with slight
modification: the BFP+ sgRNA-expressing/mCherry+ CRISPRi cells were mixed
with mCherry+ only CRISPRi cells at a 1:1 ratio. The gating strategy for flow
cytometry data analysis is shown in Supplementary Fig. 14.
cDNA synthesis and quantitative real-time PCR. Total RNA was extracted using
the RNAzol®RT reagent (Sigma) according to the manufacturer’s protocol. The
concentration and quality of the RNA were determined by using the NanoDrop
1000 spectrophotometer (Thermo). RNA (500 ng) was converted into cDNA using
the High-Capacity cDNA Reverse Transcription Kit (Thermo) according to the
manufacturer’s recommendations. cDNA was either stored at −20 °C or used for
qRT-PCR gene expression analysis. qRT-PCR was performed using the 2× TaqMan
Fast Advanced master mix (Thermo) and 20x pre-designed TaqMan gene
expression probes (Thermo) on the StepOnePlusTM Real-Time PCR instrument
(Thermo). The following TaqMan probes were used: KLF6 (Hs00810569_m1),
EPAS1 (Hs01026149_m1), PDGFB (Hs00966522_m1), CXCR4 (Hs00607978_s1),
CCND1 (Hs00765663_m1), VEGFA (Hs00900055_m1), BHLHE40
(Hs01041212_m1), SREBF1 (Hs01088679_g1), SREBF2 (Hs01081784_m1), SCD
(Hs01682761_m1), LSS (Hs01552331_m1), E2F1 (Hs00153451_m1), CPT1A
(Hs00912671_m1) and TBP (Hs00427620_m1). The Ct values of the gene of
interest were normalized using the Ct value of the housekeeping control, TBP. The
fold change of the gene expression was calculated using the 2−ΔΔCt method.
Protein extraction and western blotting. Cells were either trypsinized or scraped
on ice, washed once with 1× ice-cold PBS and lysed on ice in RIPA lysis buffer
(Sigma-Aldrich) containing 1:100 1× protease inhibitor cocktail (Sigma-Aldrich)
and 1:100 1× phosphatase inhibitor cocktail (Sigma-Aldrich). The protein lysates
were quantified using the Pierce BCA Protein Assay Kit (Life Technologies)
according to the manufacturer’s protocols. Proteins were separated using SDS-
PAGE gels and transferred onto PVDF membrane (Millipore). The membrane was
blotted with primary antibody overnight at 4 °C. Antibodies used were KLF6 (Santa
Cruz Biotech, sc-7158, 1:1000), HIF2A (Novus Biologicals, NB100-122, 1:1000),
VHL (BD Biosciences, 564183, 1:1000), P-p70 S6-kinase (Cell Signaling Technol-
ogy, Thr389, #9205, 1:1000), p70-S6-kinase (Cell Signaling Technology, #9202,
1:1000), P-S6 ribosomal (Cell Signaling Technology, Ser235/236, #4857, 1:3000), S6
ribosomal (Cell Signaling Technology, #2317, 1:1000), SREBP1 (Santa Cruz Bio-
tech, sc-13551, 1:100), SREBP2 (Santa Cruz Biotech, sc-13552, 1:100), and B-actin
(Sigma-Aldrich, A1978, 1:20000). Secondary antibodies were polyclonal goat anti-
mouse IgG/HRP (Dako, P0447, 1:10000) and polyclonal goat anti-rabbit IgG/HRP
conjugated (Dako, P0448, 1:5000). For the assessment of mTORC1 activity, cells
were serum-starved overnight and protein was extracted followed by Western
blotting. For the PDGFB supplementation experiment, cells starved overnight were
treated with either 10 ng/mL recombinant human PDGF-BB (Peprotech #100-14B)
or vehicle control for one hour. Full scans of Western blots are in Supplementary
Fig. 15.
Exogenous cDNA expression. KLF6 cDNA was amplified from 786-M1A cells
and cloned into pLVX-Puro. Primers to amplify KLF6 cDNA are listed in Sup-
plementary Table 2. For the CRISPR-Cas9 competitive proliferation rescue assay,
the sgRNA binding site of the exogenous KLF6 was synonymously mutated by site-
directed mutagenesis.
Total cholesterol quantification. Lipids were extracted from cells using the
chloroform-free lipid extraction kit (ab211044, Abcam) according to the manu-
facturer’s recommendation. Briefly, cells were agitated in the extraction buffer for
20 min at room temperature, spun down and the supernatant was dried overnight
at 37 °C. The lipid extract was resuspended in suspension buffer and sonicated for
20 min followed by agitation at 37 °C for 20 min. Total cholesterol was quantified
using the Amplex Red Cholesterol Assay Kit (A12216, Invitrogen) according to the
manufacturer’s protocol. Total cholesterol was normalized to the total protein
amount for each sample.
Statistical analyses. Statistical analyses were performed either in R or GraphPad
Prism (Version 5). Sample sizes are denoted in figure legends. No statistical method
was used to predetermine the sample size. P-values lower than 0.05 were considered
statistically significant. For animal bioluminescence, tumour growth data and his-
tological tumour count data a two-tailed Mann–Whitney U-test was used. No
animals were excluded from the analyses. For histological tumour count analyses
the experimental groups were blinded, for other experiments the experimental
groups were not randomized or blinded. For parametric tests data normality was
assessed using the Shapiro-Wilk test, variance between the groups was not assumed
to be equal. No corrections for multiple testing were made. For competitive pro-
liferation assays, cholesterol quantification and in vitro drug experiments data a
two-tailed unpaired t-test with Welch approximation was used. For qRT-PCR, three
independent experiments are shown unless stated otherwise in the figure legend,
each of the experiment is the average of three technical replicates. Boxplots repre-
sent median and 25th and 75th percentiles, whiskers as indicated in figure legends.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Code availability. Custom code used in this study are available from the corre-
sponding author on request.
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Data availability
Previously published ChIP-seq and RNA-seq data were re-analysed from the GEO data
set GSE98015 and the SRA data sets SRP007993, SRP028819, SRP097662, SRP012412.
The RNA-seq and ChIP-seq data generated during this study have been deposited to
GEO under the access codes GSE115763 and GSE115749. Human RNA-seq data for
different tumour types were downloaded from the TCGA data portal (http://tcga-data.
nci.nih.gov/).
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